Novan (NOVN) Focuses Strategic Direction and Announces Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Novan Focuses Strategic Direction and Announces Restructuring
May 31, 2023 4:05 PM EDT Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum
Process to explore a sale or out-license of commercial assets or other business transaction continues
Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3%
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to sharpen its focus and resources on berdazimer gel, 10.3%... More
